Evidence map›Paper›PMID 36829616›Full record

ReviewBioengineering (Basel, Switzerland)2023

Bioengineering of Antibody Fragments: Challenges and Opportunities.

Sama Pirkalkhoran, Wiktoria Roksana Grabowska, Hamid Heidari Kashkoli, Reihaneh Mirhassani, David Guiliano, Colin Dolphin, Hanieh Khalili

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Bioengineering (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Recombinant Protein Drugs: A 2025 Update.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  5. T-cell Receptor (TCR) Targeting with Multivalent T-cell Engagers.bioRxiv : the preprint server for biology · 2026
    Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. In vivo CAR cell therapy: from bench to bedside.Journal of hematology & oncology · 2025
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sama PirkalkhoranSchool of Biomedical Science, University of West London, London W5 5RF, UK.
Wiktoria Roksana GrabowskaSchool of Biomedical Science, University of West London, London W5 5RF, UK.
Hamid Heidari KashkoliSchool of Biomedical Science, University of West London, London W5 5RF, UK.
Reihaneh MirhassaniNivad Pharmed Salamat Company Research Center, Tehran 1455714138, Iran.
David GuilianoSchool of Life Science, College of Liberal Arts and Sciences, University of Westminster, London W1W 6UW, UK.
Colin DolphinSchool of Biomedical Science, University of West London, London W5 5RF, UK.
Hanieh KhaliliSchool of Biomedical Science, University of West London, London W5 5RF, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody fragments are used in the clinic as important therapeutic proteins for treatment of indications where better tissue penetration and less immunogenic molecules are needed. Several expression platforms have been employed for the production of these recombinant proteins, from which

Indexed as

antibody fragmentsbaculovirus expression systembioengineeringbiotherapeuticsplants expression system

Identifiers

PMID36829616
PMCPMC9952581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.